2022
Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions
Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.Peer-Reviewed Original ResearchConceptsPI-RADS 3 lesionsHigher prostate specific antigen densitySignificant prostate cancerProstate-specific antigen densityPrior negative biopsyNegative biopsyMagnetic resonance imagingProstate cancerPSA densityValidation cohortEquivocal lesionsAntigen densityResonance imagingMultivariable logistic regression modelData System (PI-RADS) 3 lesionsMultiparametric magnetic resonance imagingElevated PSA densityMulti-institutional analysisDecision curve analysisProstate Imaging ReportingDetection of csPCaLogistic regression modelsMultivariable analysisSubsequent biopsyTraining cohort
2016
MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsyProstate cancer detection rates of negative MP-MRIs.
Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.Peer-Reviewed Original ResearchTemplate mapping biopsyNegative predictive valueNegative MRIMapping biopsyActive surveillanceSignificant cancerProstate cancer detection rateSignificant CaPMRI-US fusion biopsyHigh negative predictive valueBiopsy-naive menPrior negative biopsyBiopsy-naïve patientsCancer detection rateProstate cancer detectionDiffusion-weighted imagingDynamic contrast enhancementNIH National InstituteNaïve patientsNegative menGleason 7High suspicionNegative biopsyPatient counselingGleason 4
2015
Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy.
Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.Peer-Reviewed Original ResearchCancer detection rateOverall cancer detection rateSignificant prostate cancerProstate cancerSystematic biopsyProstate biopsyFusion biopsyCommon solid organ malignancyEndorectal coilCores TRUS biopsyPrior negative biopsySolid organ malignanciesFusion prostate biopsyCochran-Armitage trend testCause of cancerMagnetic resonance imagingReal-time ultrasoundArmitage trend testAbnormal DRELesion stratificationElevated PSAOrgan malignanciesLesion gradingNegative biopsyTRUS biopsy